

HEMISPHERX BIOPHARMA INC
Form 10-Q
November 16, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
Quarterly Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

For the Quarterly Period Ended September 30, 2015

Commission File Number: 1-13441

HEMISPHERX BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

52-0845822
(I.R.S. Employer
Identification No.)

1617 JFK Boulevard, Suite 500, Philadelphia, PA 19103
(Address of principal executive offices) (Zip Code)

(215) 988-0080
(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files).

Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer Accelerated filer
 Non-accelerated filer Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes No

247,516,987 shares of common stock were outstanding as of November 1, 2015.

PART I - FINANCIAL INFORMATION

ITEM 1: Financial Statements

HEMISPHERX BIOPHARMA, INC. AND SUBSIDIARIES

Consolidated Balance Sheets

(in thousands, except for share and per share amounts)

	September 30, 2015 (Unaudited)	December 31, 2014 (Audited)
ASSETS		
Current assets:		
Cash and cash equivalents	\$1,161	\$2,156
Marketable securities	11,214	13,952
Inventory-work in process	1,326	—
Prepaid expenses and other current assets	278	399
Total current assets	13,979	16,507
Property and equipment, net	11,501	4,601
Patent and trademark rights, net	883	861
Construction in progress	—	7,337
Other assets	134	134
Total assets	\$26,497	\$29,440
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$1,506	\$2,081
Accrued expenses	1,818	2,333
Current portion of capital lease	3	22
Total current liabilities	3,327	4,436
Commitments and contingencies (Note 6)	—	—
Stockholders' equity:		
Preferred stock, par value \$0.01 per share, authorized 5,000,000; issued and outstanding; none	—	—
Common stock, par value \$0.001 per share, authorized 350,000,000 shares; issued and outstanding 247,557,287 and 204,004,818, respectively	248	204
Additional paid-in capital	313,185	302,729
Accumulated other comprehensive loss	(401) (160
Accumulated deficit	(289,862) (277,769
Total stockholders' equity	23,170	25,004
Total liabilities and stockholders' equity	\$26,497	\$29,440

See accompanying notes to consolidated financial statements.

HEMISPHERX BIOPHARMA, INC. AND SUBSIDIARIES
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
(Unaudited)

	Three months ended September 30,		Nine months ended September 30,	
	2015	2014	2015	2014
Revenues:				
Clinical treatment programs	\$23	\$45	\$106	\$157
Total revenues	23	45	106	157
Costs and expenses:				
Production	353	306	1,232	923
Research and development	1,968	1,894	7,081	6,550
General and administrative	1,685	2,174	5,600	7,210
Total costs and expenses	4,006	4,374	13,913	14,683
Operating loss	(3,983) (4,329) (13,807) (14,526
Interest expense	(1) (3) (3) (9
Interest and other income/expense	181	130	343	414
Redeemable warrants valuation adjustment	—	—	—	1
Gain from sale of income tax net operating losses	—	—	1,374	1,126
Net loss	(3,803) (4,202) (12,093) (12,994
Other comprehensive income (loss):				
Unrealized gain (loss) on marketable securities	(215) (169) (241) —
Net comprehensive loss	\$(4,018) \$(4,371) \$(12,334) \$(12,994
Basic and diluted loss per share	\$(0.02) \$(0.02) \$(0.05)